Can I stop using Etrasimod-Velsipity once I start using it?

Etrasimod is a once-daily oral small molecule S1P receptor modulator, mainly used for the treatment of moderately to severely active ulcerative colitis (UC). Many patients have questions when using this drug: Once they start taking the drug, do they have to continue using it for a long time and cannot stop taking it? In fact, the principles of use of itrimod are closely related to its mechanism of action.

Itramod reduces the inflammatory response and improves the symptoms of ulcerative colitis by regulating the distribution of lymphocytes in the intestine. This mechanism of action means that the drug can continue to suppress inflammation, but once the drug is stopped, lymphocytes in the body may re-enter the intestines, and the inflammatory response may relapse. Therefore, in clinical practice, itridimod is usually used for maintenance treatment and continuation treatment of remission induction. For patients whose condition is stable, doctors may decide whether to gradually adjust the dose or take medication intermittently based on disease assessment, but strict follow-up and monitoring are required.

It should be noted that discontinuation of medication is not absolutely prohibited, but needs to be decided by a professional doctor after assessing the risks and benefits. In clinical studies, some patients may maintain remission for a period of time after gradually reducing the dose or discontinuing the drug, but the long-term effects and risk of recurrence require individual judgment. Therefore, for most patients with moderate to severe active UC, the continuous use of itrimod helps maintain intestinal mucosal healing and symptom control, and is an important strategy to extend the symptom-free period and improve quality of life.

In addition, patients should regularly review blood indicators, colonoscopy evaluation and symptom monitoring while using itramod, so that doctors can adjust treatment plans based on efficacy and safety. For patients who experience adverse reactions, the risk can also be managed by adjusting the dose or temporarily discontinuing the drug, but this must be done under guidance.

Reference materials:https://www.drugs.com/mtm/etrasimod.html